Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer's disease

Whiley, LukeLukeWhileyChappell, Katie E.Katie E.ChappellD'Hondt, EllieEllieD'HondtLewis, Matthew R.Matthew R.LewisJimenez, BeatrizBeatrizJimenezSnowden, Stuart G.Stuart G.SnowdenSoininen, HilkkaHilkkaSoininenKloszewska, IwonaIwonaKloszewskaMecocci, PatriziaPatriziaMecocciTsolaki, MagdaMagdaTsolakiVellas, BrunoBrunoVellasSwann, Jonathan R.Jonathan R.SwannHye, AbdulAbdulHyeLovestone, SimonSimonLovestoneLegido-Quigley, CristinaCristinaLegido-QuigleyHolmes, ElaineElaineHolmes2022-02-232022-02-2320211758-9193WOS:000606419700001https://imec-publications.be/handle/20.500.12860/39062Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer's diseaseJournal article10.1186/s13195-020-00741-zWOS:000606419700001QUINOLINIC ACIDPLASMA BIOMARKERSTRANSGENIC MICEGUT MICROBIOTAINFLAMMATIONPERFORMANCEDISCOVERYDEMENTIASYSTEMMEDLINE:33422142